Original Research
Published on 06 Jun 2022
JAK1/2 Inhibitor Baricitinib Improves Skin Fibrosis and Digital Ulcers in Systemic Sclerosis
in Dermatology
Frontiers in Medicine
doi 10.3389/fmed.2022.859330
- 12,298 views
- 39 citations
40 articles related to "Jak12"
Articles
Mini Review
Published on 29 Jun 2023
Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor
in Cancer Endocrinology
Frontiers in Endocrinology
doi 10.3389/fendo.2023.1141029
- 12,775 views
- 2 citations
Original Research
Published on 07 Mar 2019
Inhibition of JAK1/2 Tyrosine Kinases Reduces Neurogenic Heterotopic Ossification After Spinal Cord Injury
in Inflammation
Frontiers in Immunology
doi 10.3389/fimmu.2019.00377
- 8,483 views
- 45 citations
Original Research
Published on 31 Aug 2021
The Effect of JAK1/2 Inhibitors on HIV Reservoir Using Primary Lymphoid Cell Model of HIV Latency
in Viral Immunology
Frontiers in Immunology
doi 10.3389/fimmu.2021.720697
- 9,960 views
- 30 citations
Brief Research Report
Published on 22 Apr 2021
Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome
in Inflammation Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2021.650295
- 8,856 views
- 39 citations
Original Research
Published on 30 Sep 2024
Unveiling signaling pathways inducing MHC class II expression in neutrophils
in Molecular Innate Immunity
Frontiers in Immunology
doi 10.3389/fimmu.2024.1444558
- 6,089 views
- 7 citations
Correction
Published on 05 Jan 2023
Corrigendum: JAK1/2 inhibitor baricitinib improves skin fibrosis and digital ulcers in systemic sclerosis
in Dermatology
Frontiers in Medicine
doi 10.3389/fmed.2022.1125836
- 2,466 views
- 4 citations
Original Research
Published on 24 Sep 2021
Venetoclax or Ruxolitinib in Pre-Transplant Conditioning Lowers the Engraftment Barrier by Different Mechanisms in Allogeneic Stem Cell Transplant Recipients
in Alloimmunity and Transplantation
Frontiers in Immunology
doi 10.3389/fimmu.2021.749094
- 6,708 views
- 12 citations
Original Research
Published on 03 Feb 2022
FUS-DDIT3 Fusion Oncoprotein Expression Affects JAK-STAT Signaling in Myxoid Liposarcoma
in Molecular and Cellular Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.816894
- 7,166 views
- 16 citations
Case Report
Published on 12 Jun 2025
Ruxolitinib in adult dermatomyositis with anti-TIF1Îł antibody: a case report and literature review
in Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Frontiers in Immunology
doi 10.3389/fimmu.2025.1591631
- 3,367 views
Original Research
Published on 26 Jan 2023
JAK inhibitors differentially modulate B cell activation, maturation and function: A comparative analysis of five JAK inhibitors in an in-vitro B cell differentiation model and in patients with rheumatoid arthritis
in Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Frontiers in Immunology
doi 10.3389/fimmu.2023.1087986
- 11,641 views
- 16 citations
Case Report
Published on 01 Apr 2025
Case Report: Diagnosis and successful treatment of a rare case of steroid-refractory chronic graft-vs-host disease-related serositis
in Alloimmunity and Transplantation
Frontiers in Immunology
doi 10.3389/fimmu.2025.1546599
- 2,886 views
- 2 citations
Original Research
Published on 16 Apr 2018
Implication of Interleukin-12/15/18 and Ruxolitinib in the Phenotype, Proliferation, and Polyfunctionality of Human Cytokine-Preactivated Natural Killer Cells
in NK and Innate Lymphoid Cell Biology
Frontiers in Immunology
doi 10.3389/fimmu.2018.00737
- 12,642 views
- 51 citations
Case Report
Published on 30 Jul 2024
A double-edged sword: unusual multiple severe infections with pralsetinib: a case report and literature review
in Infectious Diseases: Pathogenesis and Therapy
Frontiers in Medicine
doi 10.3389/fmed.2024.1402902
- 2,831 views
- 4 citations
Review
Published on 20 Aug 2025
Dual regulation of gastrointestinal tumor progression by the IFN-Îł/STAT1 pathway and prospects for targeted therapy
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1598170
- 2,391 views
- 2 citations
Brief Research Report
Published on 05 Jun 2020
Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study
in Inflammation Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2020.00857
- 11,985 views
- 109 citations